Business Description
Verrica Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92511W1080
Description
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.49 | |||||
| Equity-to-Asset | -1.03 | |||||
| Debt-to-Equity | -1.38 | |||||
| Debt-to-EBITDA | -0.63 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -18.4 | |||||
| Beneish M-Score | -4.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.5 | |||||
| 3-Year EPS without NRI Growth Rate | 5.9 | |||||
| 3-Year FCF Growth Rate | 12.2 | |||||
| 3-Year Book Growth Rate | -28.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 39.45 | |||||
| Future 3-5Y Total Revenue Growth Rate | 95.28 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 86.41 | |||||
| 9-Day RSI | 66.29 | |||||
| 14-Day RSI | 54.83 | |||||
| 6-1 Month Momentum % | -82.36 | |||||
| 12-1 Month Momentum % | -59.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.34 | |||||
| Quick Ratio | 1.22 | |||||
| Cash Ratio | 1.09 | |||||
| Days Inventory | 277.93 | |||||
| Days Sales Outstanding | 249.89 | |||||
| Days Payable | 276.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.6 | |||||
| Shareholder Yield % | -30.54 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.08 | |||||
| Operating Margin % | -815.51 | |||||
| Net Margin % | -922.81 | |||||
| FCF Margin % | -647.09 | |||||
| ROE % | -2619.46 | |||||
| ROA % | -128.78 | |||||
| ROIC % | -467.81 | |||||
| ROC (Joel Greenblatt) % | -1764.25 | |||||
| ROCE % | -156.8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.26 | |||||
| EV-to-EBIT | -1.8 | |||||
| EV-to-EBITDA | -1.83 | |||||
| EV-to-Revenue | 14.82 | |||||
| EV-to-Forward-Revenue | 8.46 | |||||
| EV-to-FCF | -2.29 | |||||
| Earnings Yield (Greenblatt) % | -55.56 | |||||
| FCF Yield % | -53.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRCA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verrica Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.21 | ||
| EPS (TTM) ($) | -1.84 | ||
| Beta | 1.75 | ||
| Volatility % | 137.04 | ||
| 14-Day RSI | 54.83 | ||
| 14-Day ATR ($) | 0.147681 | ||
| 20-Day SMA ($) | 0.992665 | ||
| 12-1 Month Momentum % | -59.52 | ||
| 52-Week Range ($) | 0.7043 - 11.41 | ||
| Shares Outstanding (Mil) | 90.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verrica Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verrica Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Verrica Pharmaceuticals Inc Frequently Asked Questions
What is Verrica Pharmaceuticals Inc(VRCA)'s stock price today?
The current price of VRCA is $1.24. The 52 week high of VRCA is $11.41 and 52 week low is $0.70.
When is next earnings date of Verrica Pharmaceuticals Inc(VRCA)?
The next earnings date of Verrica Pharmaceuticals Inc(VRCA) is 2025-02-28 Est..
Does Verrica Pharmaceuticals Inc(VRCA) pay dividends? If so, how much?
Verrica Pharmaceuticals Inc(VRCA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers